185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trialH. S. Rugo, Shanu Modi, Eriko Tokunaga et al.|ESMO Open|2023Cited by 11